Loading clinical trials...

Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level

Diagnostic Accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the Evaluation of Recurrent Papillary Thyroid Carcinoma With Patient's Raised Thyroglobulin Level in Lahore

NCT07062211•Superior University

View on ClinicalTrials.gov

Summary

This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level in Lahore.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients include both male and female from 18years to 80years
•Patients presented with raised thyroglobulin
•Patients with suspected diagnosis of recurrent papillary thyroid carcinoma

Exclusion Criteria

•Patients exclude both male and female below 18years and above 80years
•All the patients presented with carcinoma other than papillary carcinoma.
•All the patients with normal thyroglobulin level.

Locations (1)

INMOL hospital

Lahore, Punjab Province, Pakistan

Key Dates

Start Date

March 17, 2025

Primary Completion Date

September 1, 2025

Completion Date

March 1, 2026

Last Updated

July 14, 2025

Enrollment

ACTUAL participants

Conditions

Papillary Thyroid Carcinoma

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

NCT04624477

Papillary Thyroid CancerPapillary Thyroid Carcinoma+1 more

View study

COMPLETEDNA

Safety of Endoscopic Thyroidectomy Via Retro-Auricular Single-Site Approach, Transoral Approach and Transareola

NCT05760690

Papillary Thyroid Carcinoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level

Inclusion Criteria

Exclusion Criteria

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

Safety of Endoscopic Thyroidectomy Via Retro-Auricular Single-Site Approach, Transoral Approach and Transareola

Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?